Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced promising Phase 3 results for their injected glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonist in obesity. In the Chinese trial, treated patients achieved an average weight loss near 18% at 48 weeks with a dose-dependent response and no late plateau. Approximately 90% of participants lost at least 5% of weight, and over 44% achieved at least 20% loss. Adverse events were mostly mild or moderate and gastrointestinal in nature. Hengrui plans to seek regulatory approval in China promptly, while Kailera will initiate global studies with higher doses and longer duration. The development of this dual agonist reflects the increasing interest in multi-receptor therapies for obesity, as competition heats up following successes like Eli Lilly's Zepbound.